Lupin has received approval from China's National Medical Products Administration for its Oseltamivir Phosphate Oral Suspension, marking the company's first product entry into the Chinese market. The approval was granted for an Abbreviated New Drug Application in partnership with Yabao Pharmaceuticals, a leader in China's pediatric medicine market. This milestone represents a significant step in Lupin's global expansion strategy.

Approval Details

The following table summarizes the key details of this regulatory milestone:

Significance of the Approval

Oseltamivir Phosphate is an antiviral agent indicated for the treatment of influenza A and B in patients two weeks of age and older, and for prevention in individuals one year of age and older. The oral suspension form is particularly relevant for pediatric and other patient populations requiring liquid formulations. Securing approval in China, one of the largest pharmaceutical markets globally, allows Lupin to expand access to high-quality, affordable medicines.

Fabrice Egros, President - Corporate Development, Lupin, stated that the approval is a strategic step into one of the world's largest pharmaceutical markets. He emphasized the shared commitment to expanding access to therapies, particularly in pediatric care. Wei Ren, President of Yabao, noted that the approval reinforces Yabao's dedication to quality pediatric medicines and showcases the strong collaboration between the two entities.

Lupin witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 75,090 shares transacted in a single deal. The trade was executed at a price of Rs. 2289.30 per share, aggregating to a total transaction value of Rs. 17.19 crores.

Block Trade Details

The following table summarizes the key parameters of the block trade recorded on the NSE:

Block trades are large-volume transactions typically executed by institutional investors or high-net-worth participants, and are carried out outside the regular open market order book to minimize price impact. The execution of such a trade in Lupin reflects significant institutional-level activity in the stock.